GBX1,801 support keeps GSK stock in a tight range

Traders Union
All News
Financial News
GSK slips 0.03% to GBX1,844.00 today

Highlights

GSK initiated the final £180 million tranche of its £2 billion share buyback, tightening market liquidity through continued repurchases.
The company secured an exclusive partnership with Chia Tai Tianqing Pharmaceutical to advance bepirovirsen for hepatitis B in mainland China, expanding therapeutic market access.
Shares remain under persistent bearish momentum, trading below key moving averages, with expected price consolidation between GBX 1,850.00 and GBX 1,876.50 and limited upside probability.

Liquidity withdrawal and China deal increase amid selling pressure

GSK launched the fifth and final tranche of its £2 billion share buyback programme on May 11, 2026, initiating up to £180 million in new repurchases to be executed by late June. This phase comes after the prior acquisition of roughly 114.4 million shares totalling £1.82 billion, illustrating ongoing withdrawal of liquidity from the market. Also on May 11, GSK signed an exclusive partnership with Chia Tai Tianqing Pharmaceutical to accelerate the development and commercialization of bepirovirsen for chronic hepatitis B in mainland China, supporting future access to an important therapeutic market. These corporate actions reflect a period of active capital deployment and strategic expansion, though price action has remained under broader selling pressure.

Oversold signals deepen as downside momentum tests support zones

GBX 1,844.00 is positioned below the MA-20 at GBX 2,011.23 and the MA-50 at GBX 2,045.71, with the MA-200 providing underlying support at GBX 1,801.32. The Ichimoku Kijun line is set at GBX 2,016.75, marking immediate resistance. Bearish momentum is confirmed as both the MACD and ADX signal continued downward bias on the daily chart. RSI stands at 27.40, Stoch RSI at 5.93, and CCI at -104.17, all indicating deeply oversold levels, while BBP at -59.77 demonstrates seller dominance intraday. The Awesome Oscillator aligns with this selling trend. After a downside opening gap, price has moved toward the high end of the current session, with low intraday volatility and oscillators diverging from persistent negative momentum.

Limited rebound prospects as volatility band constrains outlook

Over the next five trading days, GSK is expected to oscillate within a typical volatility band ranging from GBX 1,850.00 to GBX 1,876.50. The probability of a meaningful price rebound is low — under 20% — so further softening or tight sideways movement prevails in the base case. A break above resistance at GBX 2,016.75 is required to shift the bias to bullish, while any move below the MA-200 near GBX 1,801.00 would accelerate downside risk.

Anton Kharitonov, analyst at Traders Union, sees GSK's share buyback and Chinese partnership as strategic positives, but notes that price action remains weak. Technical indicators confirm a firmly bearish trend with deeply oversold readings and no sign of rebound. He remains cautious while price stays below key resistance at GBX 2,016.75. "Base case remains defensive — until we see a break above resistance, I expect only limited upside and further consolidation."

Earlier, analysts noted that GSK faced persistent technical challenges and downside risk driven by weak momentum and resistance overhead. With fresh capital returns underway but indicators confirming deep oversold conditions, traders should closely monitor price action around the MA-200 for early signs of either renewed support or an acceleration of selling pressure.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.